Home / Therapeutic Area / Sickle Cell Disease Drug Development Pipeline Review, 2017

Sickle Cell Disease Drug Development Pipeline Review, 2017

Published: Nov 2017 | Published By: GBI Research

Description

This report provides an overview of the Sickle Cell Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for sickle cell anemia and vaso-occlusive crisis associated with sickle cell disease, and features dormant and discontinued projects.

Sickle cell anemia is a genetic (inherited) blood disorder in which red blood cells, which carry oxygen around the body, develop abnormally. Signs and symptoms include anemia, delayed growth, vision problems, pain and frequent infections. There are a total of 62 products in development for this indication, by 45 companies and nine academic institutions. Hemoglobin and a range of histone deacetylases are the most common molecular targets being studied in sickle cell anemia.

Vaso-occlusive crisis associated with sickle cell disease is a painful episode that occurs in people who have sickle cell anemia. Symptoms include fever, pain, fatigue, abdominal pain and swelling, headaches, shortness of breath, dehydration and infection. There are a total of 10 products in development for this indication.

Scope

  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons To Buy

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Executive Summary

3 Introduction
3.1 Sickle Cell Disease Report Coverage
3.2 Sickle Cell Disease – Overview
3.3 Vaso-Occlusive Crisis Associated With Sickle Cell Disease – Overview
3.4 GBI Research Report Guidance

4 Therapeutics Development
4.1 Sickle Cell Disease
4.1.1 Pipeline Overview
4.1.2 Pipeline by Companies
4.1.3 Pipeline by Universities/Institutes
4.1.4 Products under Development by Companies
4.1.5 Products under Development by Universities/Institutes
4.2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease
4.2.1 Pipeline Overview
4.2.2 Pipeline by Companies
4.2.3 Products under Development by Companies

5 Therapeutics Assessment
5.1 Sickle Cell Disease
5.1.1 Assessment by Target
5.1.2 Assessment by Mechanism of Action
5.1.3 Assessment by Route of Administration
5.1.4 Assessment by Molecule Type
5.2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease
5.2.1 Assessment by Target
5.2.2 Assessment by Mechanism of Action
5.2.3 Assessment by Route of Administration
5.2.4 Assessment by Molecule Type

6 Companies Involved in Therapeutics Development
6.1 Sickle Cell Disease
6.1.1 Acceleron Pharma Inc
6.1.2 Addmedica SAS
6.1.3 Angiocrine Bioscience Inc
6.1.4 Annexin Pharmaceuticals AB
6.1.5 ArQule Inc
6.1.6 Bio Products Laboratory Ltd
6.1.7 Bioverativ Inc
6.1.8 bluebird bio Inc
6.1.9 Bristol-Myers Squibb Co
6.1.10 Calimmune Inc
6.1.11 CRISPR Therapeutics
6.1.12 CSL Ltd
6.1.13 Daiichi Sankyo Co Ltd
6.1.14 Editas Medicine Inc
6.1.15 Errant Gene Therapeutics LLC
6.1.16 Gamida Cell Ltd
6.1.17 Genethon SA
6.1.18 Gilead Sciences Inc
6.1.19 Global Blood Therapeutics Inc
6.1.20 Incyte Corp
6.1.21 Ironwood Pharmaceuticals Inc
6.1.22 La Jolla Pharmaceutical Company
6.1.23 MaxCyte Inc
6.1.24 Merck & Co Inc
6.1.25 Morphogenesis Inc
6.1.26 NKT Therapeutics Inc
6.1.27 Novartis AG
6.1.28 Orphagen Pharmaceuticals Inc
6.1.29 Prolong Pharmaceuticals LLC
6.1.30 Protagonist Therapeutics Inc
6.1.31 ReveraGen BioPharma Inc
6.1.32 Sancilio & Company Inc
6.1.33 Sangamo Therapeutics Inc
6.2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease
6.2.1 AstraZeneca Plc
6.2.2 Bristol-Myers Squibb Co
6.2.3 Gilead Sciences Inc
6.2.4 Modus Therapeutics Holding AB
6.2.5 Novartis AG
6.2.6 NuvOx Pharma LLC
6.2.7 Pfizer Inc
6.2.8 Prolong Pharmaceuticals LLC
6.2.9 Seattle Genetics Inc

7 Dormant Projects
7.1 Sickle Cell Disease
7.2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease

8 Discontinued Products
8.1 Vaso-Occlusive Crisis Associated With Sickle Cell Disease

9 Product Development Milestones
9.1 Sickle Cell Disease
9.1.1 Featured News & Press Releases
9.2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease
9.2.1 Featured News & Press Releases

10 Appendix
10.1 Methodology
10.2 Coverage
10.3 Secondary Research
10.4 Primary Research
10.5 Expert Panel Validation
10.6 Contact Us
10.7 Disclaimer

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +